Koshinski Asset Management Inc. Grows Position in Quest Diagnostics Incorporated $DGX

Koshinski Asset Management Inc. raised its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 14.2% in the second quarter, Holdings Channel reports. The institutional investor owned 1,700 shares of the medical research company’s stock after buying an additional 212 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Quest Diagnostics were worth $305,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Pinnacle Bancorp Inc. raised its stake in Quest Diagnostics by 126.9% during the second quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock valued at $27,000 after buying an additional 85 shares during the last quarter. First Horizon Advisors Inc. raised its stake in Quest Diagnostics by 76.6% during the first quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock valued at $32,000 after buying an additional 82 shares during the last quarter. Golden State Wealth Management LLC raised its stake in Quest Diagnostics by 157.3% during the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company’s stock valued at $33,000 after buying an additional 118 shares during the last quarter. Ameritas Advisory Services LLC purchased a new position in Quest Diagnostics during the second quarter valued at $35,000. Finally, Continuum Advisory LLC raised its stake in Quest Diagnostics by 11,100.0% during the first quarter. Continuum Advisory LLC now owns 224 shares of the medical research company’s stock valued at $38,000 after buying an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on DGX shares. Mizuho lifted their price objective on Quest Diagnostics from $190.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday. Robert W. Baird reiterated a “neutral” rating and set a $194.00 price objective on shares of Quest Diagnostics in a research note on Monday, August 25th. Deutsche Bank Aktiengesellschaft boosted their price target on Quest Diagnostics from $160.00 to $178.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. William Blair restated an “outperform” rating on shares of Quest Diagnostics in a research note on Wednesday, July 23rd. Finally, Truist Financial set a $195.00 price target on Quest Diagnostics in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Quest Diagnostics has a consensus rating of “Moderate Buy” and a consensus target price of $189.06.

Quest Diagnostics Stock Up 0.4%

DGX stock opened at $190.26 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99. Quest Diagnostics Incorporated has a 1-year low of $146.91 and a 1-year high of $191.87. The stock has a market capitalization of $21.28 billion, a P/E ratio of 22.79, a P/E/G ratio of 2.51 and a beta of 0.56. The business has a fifty day moving average price of $182.68 and a 200-day moving average price of $176.41.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.05. The company had revenue of $2.76 billion during the quarter, compared to analysts’ expectations of $2.73 billion. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.Quest Diagnostics’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.35 earnings per share. Equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, October 20th. Investors of record on Friday, October 3rd were given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date was Friday, October 3rd. Quest Diagnostics’s dividend payout ratio is 38.32%.

Insider Activity at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 227 shares of the company’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president owned 38,117 shares in the company, valued at approximately $7,170,951.21. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Patrick Plewman sold 1,975 shares of the company’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $185.00, for a total value of $365,375.00. Following the sale, the senior vice president owned 15,269 shares of the company’s stock, valued at approximately $2,824,765. This trade represents a 11.45% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,186 shares of company stock worth $9,647,471. 8.16% of the stock is owned by insiders.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.